GSK’s follow-up to its severe asthma therapy Nucala has shown its value in a pair of phase 3 trials, reducing exacerbations compared to placebo with dosing once every six months. The company ...

The Food and Drug Administration on Tuesday approved GSK’s drug for a common type of urinary tract infection (UTI) in women and adolescent girls, one of five new approvals the British drugmaker ...

Smith announces that investors with substantial losses have opportunity to lead the securities fraud class action lawsuit against GSK plc. ("GSK" or the "Company") (NYSE: GSK). IF YOU ARE AN ...